PCOS Renamed Polyendocrine Metabolic Ovarian Syndrome

Polycystic ovary syndrome (PCOS), a hormonal condition affecting over 170 million women globally, has been officially renamed Polyendocrine metabolic ovarian syndrome (PMOS). This change, published in The Lancet and led by Monash University and the International Androgen Excess and Polycystic Ovary Syndrome Society, follows 14 years of global collaboration involving experts and patients. The previous name was deemed inaccurate and misleading, as it oversimplified the complex endocrine and metabolic disorder to a misunderstanding about ovarian cysts, leading to missed diagnoses and inadequate treatment. The new name, Polyendocrine metabolic ovarian syndrome, aims to better reflect the condition's multisystem nature, including its impacts on weight, metabolic and mental health, skin, and the reproductive system. Experts like Helena Teede and Melanie Cree believe this will lead to improved patient care, enhanced diagnosis, and greater understanding, potentially opening new research funding opportunities from organizations such as the United States — National Institutes of Health. A three-year education and awareness campaign is underway, with full integration into international guidelines expected by 2028.